Personal information

ruthenium complexes, natural products, oxidative stress, PI3K/AKT/mTOR, MAPK, NFkB and p53 signaling, hepatocellular carcinoma, colon carcinoma, acute myeloid leukemia, cancer/leukemia stem cells
Brazil

Biography

I am B.Pharm. and Ph.D in Pharmacology focused in pre-clinical development of new antineoplastic drugs. Currently, mainly involved in the study of: ruthenium complexes; natural products; oxidative stress; PI3K/AKT/mTOR, MAPK, NFkB and p53 signaling; hepatocellular carcinoma; colon carcinoma; acute myeloid leukemia; and cancer/leukemia stem cells.

Activities

Employment (2)

Oswaldo Cruz Foundation: Salvador, Bahia, BR

2013-01-07 to present | Researcher
Employment
Source: Self-asserted source
Daniel Bezerra

The University of Texas MD Anderson Cancer Center: Houston, Texas, US

2022-09-01 to 2022-12-31 | Visiting Scientist (Department of GastroIntestinal )
Employment
Source: Self-asserted source
Daniel Bezerra

Education and qualifications (3)

Weill Cornell Medicine: New York, NY, US

2019-05 to 2020-04 | Post-Doctorate
Qualification
Source: Self-asserted source
Daniel Bezerra

Federal Univerity of Ceara: Fortaleza, CE, BR

2000-03 to 2013-12 | B. Pharm.
Education
Source: Self-asserted source
Daniel Bezerra

Federal Univerity of Ceara: Fortaleza, CE, BR

2004-11-05 to 2008-06-23 | Ph.D in Pharmacology
Education
Source: Self-asserted source
Daniel Bezerra

Professional activities (2)

American Association for Cancer Research: PA, PA, US

2020-05 to present | Active member
Membership
Source: Self-asserted source
Daniel Bezerra

Brazilian Society of Pharmacology and Experimental Therapeutics (SBFTE): Rockville, MD, US

2008-11 to present | Active member
Membership
Source: Self-asserted source
Daniel Bezerra

Peer review (31 reviews for 15 publications/grants)

Review activity for Advanced science. (2)
Review activity for Bioconjugate chemistry. (1)
Review activity for Cancer communications. (3)
Review activity for Cancer letters. (1)
Review activity for Cancers. (4)
Review activity for Cell death and disease. (1)
Review activity for Cell death discovery. (4)
Review activity for Journal of biochemical and molecular toxicology. (2)
Review activity for Journal of ethnopharmacology. (3)
Review activity for Journal of experimental & clinical cancer research. (4)
Review activity for Molecules. (2)
Review activity for Nature communications (1)
Review activity for Oncogene. (1)
Review activity for Oncogenesis. (1)
Review activity for Surgical and experimental pathology. (1)